Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SuDDICU: Selective Decontamination of the Digestive Tract in ICU Patients
NCT02389036Phase 3Completed
- Sponsor
- The George Institute for Global Health
- Start
- May 2017
- Primary completion
- Apr 2023
- Modality
- Peptides, Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of colistin, tobramycin and nystatin oral suspension in critical illness, sepsis, septic shock and 1 more, sponsored by The George Institute for Global Health. Primary endpoint: Hospital Mortality at 90 days. Started May 2017; status: completed.
02
Drugs
colistintobramycinnystatin oral suspension
03
Conditions
critical illnesssepsisseptic shockventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT02389036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389036.